Evotec SE’s Seattle-based subsidiary, Just – Evotec Biologics Inc., has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just – Evotec Biologics’ molecular design suite of computational technologies, called “J.MD.”

Under the grant terms, Just – Evotec Biologics will leverage its J.MD Molecular Design service—a key component of its J.DESIGN platform, which integrates advanced computational tools and high-throughput methodologies—to streamline the biologics development process. By optimizing molecular design from the earliest stages, J.MD ensures manufacturability, stability, and efficacy—critical factors for reducing costs and enabling expansion of global access to these therapies as well as limiting liabilities like immunogenicity and instability. The new investment will enable ten new J.MD projects over the next three years, spanning the development of biotherapeutics targeting multiple global health disease indications of concern.

This grant extends the commitment of Just – Evotec Biologics, that began in 2014 and has since delivered multiple cGMP manufacturing campaigns for RSV, Malaria, and HIV monoclonal antibodies.

Dr. Linda Zuckerman, EVP and Global Head of Just – Evotec Biologics, said: “We are thrilled to receive this new grant from the Gates Foundation which will strengthen our commitment to reducing the cost of biologics development to expand global access. By leveraging our J.DESIGN platform and innovative molecular design tools, we look forward to supporting the foundation in driving impactful solutions across multiple disease areas and continuing to deliver therapies where they are needed most.”

The Latest from Evotec

Evotec recently appointed Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations.